15 completed, 1 recruiting. 10 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow PEDIARIX: new trials by email Literature Review of PEDIARIX trials Research Report on PEDIARIX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa - Healthy | Phase 3 | Recruiting | Pfizer | 6000 | 2025-08-25 | 2026-10-27 |
| Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1196 | 2018-07-27 | 2026-08-20 |
| This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine Rotarix, Pediarix, Hiberix - Rotavirus Infection, Rotavirus Vaccines | Phase 3 | Completed | GlaxoSmithKline | 1280 | 2017-09-14 | 2020-12-29 |
| Duration of Protection: GSK DTaP Vaccines Infanrix, Pediarix, Kinrix - Diphtheria, Acellular Pertussis | Completed | GlaxoSmithKline | 1 | 2015-02-01 | 2015-11-02 | |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 600 | 2014-02-01 | 2018-09-14 |
| Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™ - Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 4003 | 2010-06-18 | 2018-07-12 |
| Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines - Pertussis | Completed | Sanofi Pasteur, a Sanofi Company | 1195 | 2010-02-08 | 2022-04-25 | |
| Database Surveillance Safety Study of PENTACEL® Vaccine DTaP-IPV/Hib, Other DTap Vaccines - Diphtheria, Tetanus | Completed | Sanofi Pasteur, a Sanofi Company | 62538 | 2008-09-01 | 2015-08-19 | |
| Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Infanrix™ penta, Infanrix™ hexa - Poliomyelitis, Acellular Pertussis | Phase 4 | Completed | GlaxoSmithKline | 283 | 2008-02-14 | 2018-06-06 |
| Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix® - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1558 | 2008-02-13 | 2018-09-21 |
| A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib - Meningitis, Meningococcal | Phase 3 | Completed | Novartis Vaccines | 4545 | 2007-03-01 | 2014-03-24 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 4432 | 2006-09-01 | 2016-12-16 |
| Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 4441 | 2006-02-22 | 2018-08-24 |
| Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 2 | Completed | GlaxoSmithKline | 756 | 2004-08-01 | 2018-08-24 |
| Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine Pediarix, Licensed DTPa containing vaccine, Prevnar®: (Wyeth) - Hepatitis B, Poliomyelitis | Completed | GlaxoSmithKline | 120794 | 2003-04-01 | 2014-01-13 |
Haemophilus Infections (7) · Diphtheria (5) · Meningococcal Infections (5) · Tetanus (5) · Hepatitis B (3) · Poliomyelitis (3) · Meningitis (2) · Meningitis, Meningococcal (2) · Whooping Cough (2) · Gram-Negative Bacterial Infections (1) · Rotavirus Infections (1)
GlaxoSmithKline (12) · Sanofi Pasteur, a Sanofi Company (2) · Novartis Vaccines (1) · Pfizer (1)
United States (13) · Mexico (3) · Argentina (2) · Australia (1) · Brazil (1) · Canada (1) · Colombia (1) · Finland (1) · Japan (1) · Netherlands (1) · Philippines (1) · Puerto Rico (1) · Russia (1) · South Africa (1) · South Korea (1)
PMID 22094635, PMID 22327493, PMID 25152325, PMID 25156560, PMID 25305567, PMID 27373595, PMID 28506516, PMID 32921507
2016 (2)